

## DAFTAR PUSTAKA

- Abhishek A, *et al.* 2017. *Gout – a guide for the general and acute physicians. CME Rheumatology Clinical Medicine Vol.17 (1):54-9.*
- Afendi, F.M. *et al.* 2012. *Plant Cell Physiol.* (53) e1.1–12 doi:10.1093/pcp/pcr165
- Alegantina, S. *et al.* 2000. *Disolusi dan Penetapan Kadar Allopurinol Sediaan Generik dan Sediaan dengan Nama Dagang.* Departemen kesehatan RI. Jakarta
- Altman R, *et al.* 1986. *The American College of Rheumatology criteria for the classification and reporting of osteoarthritis os the knee.* *Arthritis Rheum.*
- Amrutha, K. *et al.* 2014. *Discovery of lesser known flavones as inhibitors of NF- $\kappa$ B signaling in MDA-MB-231 breast cancer cells-A SAR study.* *Bioorganic & Medicinal Chemistry Letters* 24(19):4735–42.
- Anastesya, W. 2009. *Arthritis Pirai (Gout) dan Penatalaksanaannya.* Fakultas Kedokteran Universitas Kristen Krida Wacana. Jakarta.
- Azari, RA. 2014. *Journal Reading: Arthritis Gout.* Semarang: Fakultas Kedokteran Universitas Islam Sultan Agung.
- Bachmann, K. 2009. *Drug Metabolism: an overview. 13-Cardiotoxicity and Cardioprotective Effects of African Medicinal Plants. Toxicological Survey of African Medicinal Plants* 2014, Pages 395-421.
- Barkas F, *et al.* 2018. *Uric acid and incident chronic kidney disease in dyslipidemic individuals.* *Curr Med Res Opin Jul;34(7):1193-1199.*
- Ben-Chetrit, E., Bergmann, S., Sood, R. 2005. *Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis.* *Rheumatology (Oxford, England)* (45) 274–282.
- Borstad G.C., *et al.* 2004. *Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.* pmid:15570646
- Boudreau, L.H. *et al.* 2012. *Caffeic Acid Phenethyl Ester and Its Amide Analogue Are Potent Inhibitors of Leukotriene Biosynthesis in Human Polymorphonuclear Leukocytes.* *PLoS ONE* 7, 31833-31838.
- Cao, H. *et al.* 2014. *X-ray Crystal Structure of a Xanthine Oxidase Complex with the Flavonoid Inhibitor Quercetin.* *J. Nat. Prod.* 77:1693-1699.
- Cartwright, T. *et al.* 2016. *NFKB1: a suppressor of inflammation, ageing and cancer.* *The FEBS Journal* Vol.283(10):1812-1822.

- Chen, I.H., *et al.* 2005. *Allopurinol-induced severe hypersensitivity with acute renal failure. Kaohsiung J. Med. Sci.* (21) 228–232.
- Cytoscape. 2021. *What is Cytoscape?.* [https://cytoscape.org/what\\_is\\_cytoscape.html](https://cytoscape.org/what_is_cytoscape.html). 3 Oktober 2021 (22.06)
- Darussalam, *et al.* 2016. *Peran Air Rebusan Daun Salam (Syzygium polyanthum) Dalam Menurunkan Kadar Asam Urat. Jurnal Ilmu Kesehatan* Vol.5(2).
- Dehghan, F. *et al.* 2014. *Effect of relaxin on the musculoskeletal system, Scandinavian Journal of Medicine & Science in Sports*, vol. 24, (4) pp. E220–E229.
- Deng, S. *et al.* 2007. *Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod.* 70(5):859-862.
- Desai, J. *et al.* 2017. *Molecular pathophysiology of gout. Trends in Molecular Medicine* Vol. 23(8), pp. 756–768.
- Dinarello, C.A. 2000. *The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med.* 343, 732–734
- Dufton J. 2011. *The Pathophysiology and Pharmaceutical Treatment of Gout.* Maryland: Pharmaceutical Education Consultants. Inc
- Enomoto A. *et al.* 2002. *Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature* 417:447–52. doi: 10.1038/nature742
- Firestein GS, *et al.* 2009. *Kelley's Textbook of Rheumatology, 8th ed.* W.B Saunders, Philadelphia 1481-1506.
- Fotis, C. *et al.* 2018. *Network-based technologies for early drug discovery. Drug Discov Today* (23) 626-635.
- Gadangi, P. *et al.* 1996. *The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol.* Mar 1;156(5):1937-41.
- Gennuso, F. *et al.* 2004. *Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc. Natl. Acad. Sci. U.S.A.* 101, 2470–2475.
- Greer, S.N. *et al.* 2012. *The update biology of hypoxia-inducible factor. The EMBO Journal* Vol.31(11):2448-2460.

- H. H. Ng, *et al.* 2019. *Relaxin and extracellular matrix remodeling: mechanisms and signaling pathways. Molecular and Cellular Endocrinology*, vol. 487, pp. 59–65.
- Haidari, F. *et al.* 2009. *Inhibitory Effects of Tart Cherry (Prunus cerasus) Juice on Xanthine Oxidoreductase Activity and its Hypouricemic and Antioxidant Effects on Rats. Malaysian Journal of Nutrition* . Vol. 15 Issue 1, p53-64.
- Haidari, F. *et al.* 2009. *Orange Juice and Hesperetin Supplementation to Hyperuricemia Rats Alter Oxidative Stress Marker and Xanthine Oxidoreductase Activity. J. Clin Biochem, Nurt*, Vol. 45(3) 285-219.
- Hande, K.R., *et al.* 1984. *Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am. J. Med.* 76, 47–56.
- Haorah, J. *et al.* 2007. *Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. Journal of Neurochemistry*, vol.101(2):566–576.
- Hari, A. *et al.* 2014. *Activation of NLRP3 inflammasome by crystalline structures via cell surface contact. Sci. Rep.* 4, 7281.
- Hasanabady, MH dan Kalalinia, F. 2016. *ABCG2 inhibitions as therapeutic approach for overcoming multidrug resistance in cancer. J. Biosci* doi:10.1007/s12038-016-9601-5.
- He, Y. *et al.* 2016. *NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature* 530, 354–357.
- Hecker, N. *et al.* 2011. *SuperTarget goes quantitative: update on drug–target interactions. Nucleic Acids Res.* 40 (D1) D1113–D1117.
- Hille, R. dan Nishino, T. 1995. *Xanthine oxidase and xanthine dehydrogenase. Federation of American Societies for Experimental Biology Volume. 9 Issues 11. Page 995-1003.*
- Hopkins, A.L. 2007. *Network pharmacology. Nature biotechnology* (25) 1110-1111.
- Hopkins, A.L. 2008. *Network pharmacology: the next paradigm in drug discovery. Nature chemical biology.* 4, pages 682–690.
- Horiuchi, H. *et al.* 2000. *Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci.* 66, 2051–2070.
- Ichida, K. *et al.* 2012. *Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Communications* 3:764.

- Inokuchi, T. *et al.* 2006. *Arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18*. *Cytokine* 33, 21-27.
- Kalpon, H. dan Reichert, J.M. 2018. *Antibodies to watch in 2018*. *mAbs*, 10(2):183-203.
- Kardinan, I. A. dan Kusuma, F. R. 2004. *Meniran penambah daya tahan tubuh alami*. AgroMedia.
- Kenyon, V. *et al.* 2011. *Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12-Lipoxygenase*. *Jour Med Chem.* 54:5485-5497.
- Kim, B.Y. *et al.* 2017. *Therapeutic properties of Scutellaria baicalensis in db/db mice evaluated using Connectivity Map and network pharmacology*, *Scientific reports* (7) 41711.
- Krapf, M.K. *et al.* 2018. *2,4,6-Substitued Quinazolines with Extraordinary Inhibitory Potency toward ABCG2*. *J. Med. Chem.* 61(17):7952-7976.
- Kumar, B dan Linert, P. 2016. *Gout and African American reducing dispaties*. Amerika: *Cleveland Clinic Journal of Medicine*.
- Kumar, S. *et al.* 2005. *Benzbromarone therapy in management of refractory gout*. *N.Z. Med. J.* 118, U1528.
- Kunishima, C. *et al.* 2007. *Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors*. *PPAR Res.* 2007, 36092.
- L. G. Pinto, *et al.* 2008. *IL-17 mediates articular hypernociception in antigen-induced arthritis in mice*. *Pain*, vol. 148(2) pp. 247–256.
- Lamprecht, P. *et al.* 2008. *New aspects of the pathogenesis of gout Danger signals, autoinflammation and beyond*. *Z. Rheumatol.* 67, 151–156
- Li, H. *et al.* 2014. *Network pharmacology approach to determine active compounds and action mechanisms of ge-gen-qin-lian decoction for treatment of type 2 diabetes*, *Evidence-based complementary and alternative medicine : eCAM*, 495840.
- Liu, P, *et al.* 2020. *Potential Molecular Mechanisms of Plantain in the Treatment of Gout and Hyperuricemia Based on Network Pharmacology*. *Evidence-Based Complementary and Alternative Medicine Volume 2020*, Article ID 3023127, 20. doi: 0.1155/2020/3023127
- Lu Y, *et al.* 2013. *Functional cooperation of SMCTs and URAT1 for renal reabsorption transport of urate*. *Drug Metab Pharmacokinet.* 28:153–8. doi: 10.2133/dmpk.DMPK-12-RG-070

- Manampiring, A.E. 2011. *Hiperurisemia dan Respon Imun. Jurnal Biomedik Vol.3* (2) doi:/10.35790
- Martin, W.J. *et al.* 2011. *Monosodium urate monohydrate crystal-recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout. Arthritis Rheum.* 63, 1322–1332.
- Martinez, Y.V. *et al.* 2007. *Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelias 15-hLO-2. Bioorg Med Chem.* 15(23):7408-7425.
- Martinon, F. *et al.* 2006. *Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature* 440, 237–241
- Misnadiarly. 2008. *Mengenal Penyakit Arthritis. Mediakom*, 57.
- Miyazawa, K.W.R. *et al.* 2017. *Quercetin inhibits gout arthritis in mice: induction of an opioid-dependent regulation of inflammasome. Inflammopharmacol* doi:10.1007/s10787-017-0356-x
- Muhtadi, *et al.* 2014. *Hyperuricemia Activity Of Salam (Syzigium polyanthum Walp.) and Meniran (Phyllanthus niruri Linn.) Herbs Extracts In Oxonate-Induced Mice. Muhammadiyah University of Surakarta.* pp.1-7.
- Mulay, S.R. *et al.* 2016. *Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat. Commun.* 7, 10274.
- Murugaiyah V. dan Chan K.L. 2006. *Antihyperuricemic Ligands From The Leaves of Phyllanthus Niruri. Planta Medica* 72:1262-1267.
- Mutschler, E. 1991. *Dinamika Obat Volume 5.* Institut Teknologi Bandung.
- National Institute for Health Research. 2018. *Emapalumab for primary haemophagocytic lymphohistiocytosis.* nihiro id:8727.
- National Institute of Diabetes and Digestive and Kidney Diseases, 2012. *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].* pmid: 31643176.
- Ng, G. *et al.* 2008. *Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity* 29, 807–818.
- Nizet, V. and Johnson, R. S. 2009. *Interdependence of hypoxic and innate immune responses. Nature Reviews Immunology*, vol. 9(9) pp. 609–617.

- Perhimpunan Reumatologi Indonesia. 2018. *Pedoman Diagnosis dan Pengelolaan Gout*. Perhimpunan Reumatologi Indonesia. Jakarta.
- Poor G, Mituszova M. 2003. *History, Classification and epidemiology of crystal-related arthropathies*. Rheumatology. 2nd ed. Edinburg: Elsevier.p.1893-1901.
- Porto C.R.C. *et al.* 2013. *Anti-inflammatory and antinociceptive activities of Phyllanthus niruri spray-dried standardized extract*. *Brazillian Jour of Pharmacognosy* 23(1):138-144.
- Qazi, Y. *et al.* 2016. *Hyperuricemia Treatment & Management*. Available at: <http://emedicine.medscape.com/article/241767treatment#%0Ashowall>.
- Reber, L.L. *et al.* 2014. *Contribution of mast cell-derived interleukin-1beta to uric acid crystal-induced acute arthritis in mice*. *Arthritis Rheumatol.* 66, 2881–2891
- Rey, A. *et al.* 2019. *Acute kidney injury associated with febuxostat and allopurinol: a post marketing study*. *Arthritis Res Ther* 21:229.
- Rivai, H., *et al.* 2013. *Karakterisasi Ekstrak Herba Meniran (Phyllanthus niruri Linn) dengan Analisa Fluorensi*. *Jurnal Farmasi Higea*, 5(2).
- Robert A. Terkeltaub, *et al.* 2010. *High Versus Low Dosing of Oral Kolkisine for Early Acute Gout Flare*. *Arthritis & Rheumatism* Vol. 62(4) pp 1060–1068.
- Robinson P.C. 2018. *Febuxostat for the treatment of hyperuricaemia in gout*. doi: 10.1080.
- Rott, K.T. & Agudelo, C.A. 2003. *Gout*. *J. Am. Med. Assoc.* 289, 2857–2860.
- Sabina, E.P. *et al.* 2011. *A role of piperine on monosodium urate crystal-induced inflammation-an experimental model of gouty arthritis*. *Inflammation* 34, 184–192.
- Schneider, H. *et al.* 2000. *Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria*. *J Appl Microbiol.* 89:1027–1037.
- Schorn, C. *et al.* 2011. *Sodium overload and water influx activate the NALP3 inflammasome*. *J. Biol. Chem.* 286, 35–41.
- Schunack, W. *et al.* 1990. *Senyawa Obat Kimia Farmasi*. Gajah Mada University Press. Yogyakarta.
- Sha, H.B. dan He, S.W. 2009. *The research progress on gout related factors and its susceptibility genes*. *Chin. J. Public Health* 25, 629–631.

- Shannon, P. *et al.* 2003. *Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks*. *Genome Res.* 13 (11), 2498–2504.
- Shi, H. *et al.* 2016. *NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component*. *Nat. Immunol.* 17, 250–258
- Silbernagl S. 2006. *Teks dan Atlas Berwarna Patofisiologi*. Jakarta : EGC Silviana
- et al.* 2015. *Hubungan Status Gizi, Asupan Bahan Makan Sumber Purin dengan Kadar Asam Urat pada Pasien Hiperuresemia Rawat Jalan di Rumah Sakit Tugurejo Semarang*.  
<http://jurnal.unimus.ac.id/index.php/jgizi/article/download/1761/1803>
- STRING. 2021. STRING Database – Content. [https://string-db.org/cgi/about?footer\\_active\\_subpage=content](https://string-db.org/cgi/about?footer_active_subpage=content). 03 Oktober 2021 (22.31)
- Strowig, T. *et al.* (2012) *Inflammasomes in health and disease*. *Nature* 481, 278–286
- Stryer, L. 2000. *Biokimia Edisi IV Vol 2*. Jakarta: EGC
- Stryer, Lubert. 2000. *Biokimia Vol. 2 Edisi 4*. JBuku Kedokteran EGC. Jakarta.
- Sudarsono, P. A. *et al.* 1996. *Tumbuhan Obat*. Yogyakarta: Pusat Penelitian Obat Tradisional Universitas Gajah Mada.
- Sullivan, S.O. *et al.* 2016. *Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis:effect on inflammation-related genes*. *British Jour of Pharm.* 174:512-524.
- Sungmin, Ko *et al.* 2009. *Structure-based virtual screening approach to the discovery of novel inhibitors of factor-inhibiting HIF-1: identification of new chelating groups for the active-site ferrous ion*. *Bioorg. Med. Chem.* 17(22):7769-74.
- SwissTargetPrediction (2021). *SwissTargetPrediction*. Retrieved from <http://www.swisstargetprediction.ch>. 21 November 2021 (19.42)
- Tausche, A.K., *et al.* 2004. *Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumor necrosis factor  $\alpha$  as a new therapeuticoption*. *Ann. Rheum. Dis.* 63, 1351–1352.
- Tong, Y., *et al.* 2013. *Progress in primary hyperuricemia and gout-related genes*. *Guide China Med.* 11, 88–89.

- Torres RJ, *et al.* 2014. *Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. J Rheumatol* 41:1863–70. doi: 10.3899/jrheum.140126
- Uniprot. 2021. *About UniProt*. <https://www.uniprot.org/help/about>. 3 Oktober 2021 (23.11)
- Van den Bossche, J. *et al.* 2017. *Macrophage immunometabolism: where are we (going)?*. *Trends in Immunology*, vol. 38(6), pp. 395–406.
- Vanden Berghe, T. *et al.* 2014. *Regulated necrosis: the expanding network of non-apoptotic cell death pathways*. *Nat. Rev. Mol. Cell Biol.* 15, 135–147
- Wahl, C. *et al.* 1998. *Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B*. *J Clin Invest.* 101(5):1163-74.
- Wang, J. and Zhao, Q. 2020. *LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-alpha*. *International Immunopharmacology*, vol. 84, 2020.
- Wang, L. *et al.* 2012. *Natural products as a gold mine for selective matrix metalloproteinases inhibitors*. *Bioorg Med Chem.* 20(13):4164-71.
- Wang, Y. *et al.* 2020. *Target Recognition and Network Pharmacology for Revealing Anti-diabetes Mechanisms of Natural Product*. *Journal of Computational Science*.45(1):1-35
- Wei W.X., *et al.* 2002. *New lignan isolated from Phyllanthus niruri – Structure elucidation by NMR spectroscopy*. In : Sjamsul Arifin Achmad, dkk. *Ilmu Kimia dan Kegunaannya : Tumbuh-Tumbuhan Obat Indonesia*. Bandung : ITB, p : 275.
- Wong I.L.K *et al.* 2009. *Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Multidrug Resistance by Bivalent Apigenin Homodimers and Their Derivatives*. *J. Med. Chem.* 52(17):5311-5322.
- World Health Organization (WHO). 2017. *WHO methods and data sources global burden of disease estimates 2000-2015*.
- Xu, S. and Cao, X.T. 2010. *Interleukin-17 and its expanding biological functions*. *Cellular & Molecular Immunology*, vol. 7(3) pp. 164–174, 2010.
- Xue, J. *et al.* 2019. *Network pharmacology-based prediction of the active ingredients, potential targets, and signaling pathways in compound Lian-Ge granules for treatment of diabetes*. *Journal of cellular biochemistry*, 120 6431-6440.



- Yang Wu, *et al.* 2018. *SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping*. *Nucleic Acids Research*, Volume 47, Issue D1, Pages D1110–D1117
- Yang, M. *et al.* 2018. *A Network Pharmacology Approach to Uncover the Molecular Mechanisms of Herbal Formula Ban-Xia-Xie-Xin-Tang, Evidence-based complementary and alternative medicine : eCAM*, 4050714.
- Yuan, C.J., *et al.* 2000. *Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs*. *Cancer Res.* 60, 1084–1091.
- Zahara, R. 2013. *Hubungan Antara Profil Pasien Dengan Frekuensi Serangan Akut Pada Pasien Arthritis Gout di RSUD Dr. Saiful Anwar Malang*. *MKI* 24(11).
- Zamudio-Cuevas, Y. *et al.* 2016. *Monosodium urate crystals induce oxidative stress in human synovio cytes*. *Arthritis Res. Ther.* 18, 117
- Zhai, L. *et al.* 2018. *Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study*, *Frontiers in pharmacology*, (9) 973.
- Zhang, J. *et al.* 2016. *Necrosome core machinery: MLKL*. *Cell. Mol. Life Sci.* 73, 2153–2163.
- Zheng, X. *et al.* 2008. *Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways*. *Proc Natl Acad Sci USA* 105:3368-3373.